4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares are trading lower by 11.7% to $28.33 Wednesday afternoon after the company announced an upsized underwritten public offering comprising 6,586,015 ...
4D Molecular Therapeutics, Inc. (FDMT) closed the last trading session at $15.62, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the ...
4D Molecular Therapeutics (NASDAQ:FDMT) stock is trading lower on Thursday after the company released interim follow-up data from the Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.
Below is Validea's guru fundamental report for 4D MOLECULAR THERAPEUTICS INC (FDMT). Of the 22 guru strategies we follow, FDMT rates highest using our Value Investor model based on the published ...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Ashoo Gupta, VP, Finance and Controller at 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), sold a total of 390 shares of common stock at a price of $8.61, for a total value of $3357, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results